ARDSLEY, N.Y.--(BUSINESS WIRE)--
Acorda Therapeutics, Inc. (Nasdaq:ACOR)
today announced that
Ron Cohen
, M.D., President and Chief Executive
Officer will present at the Stifel 2014 Healthcare Conference on
Tuesday, November 18 at 1:50pm ET.
A live audio webcast of the presentation can be accessed under “Investor
Events” in the Investor section of the Acorda website at www.acorda.com,
or you may use the link:
http://www.veracast.com/webcasts/stifel/healthcare2014/84114126772.cfm
Please log in approximately 5 minutes before the scheduled time of the
presentations to ensure a timely connection. An archived version of this
webcast will be available until December 11, 2014 on the Investors
section of www.acorda.com.
About Acorda Therapeutics
Founded in 1995, Acorda Therapeutics is a biotechnology company focused
on developing therapies that improve the lives of people with
neurological disorders.
Acorda markets three FDA-approved therapies including AMPYRA®
(dalfampridine) Extended Release Tablets, 10 mg, a treatment to improve
walking in patients with multiple sclerosis (MS), as demonstrated by an
increase in walking speed.
Acorda has one of the leading pipelines in the industry of novel
neurological therapies. The Company is currently developing six
clinical-stage therapies and one preclinical stage therapy. This
pipeline addresses a range of disorders including post-stroke deficits,
Parkinson’s disease, epilepsy, stroke, peripheral nerve damage, spinal
cord injury, neuropathic pain, and heart failure.
For more information, please visit the Company’s website at: www.acorda.com.
Forward-Looking Statements
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects should be
considered forward-looking. These statements are subject to risks and
uncertainties that could cause actual results to differ materially,
including our ability to successfully market and sell Ampyra in the
U.S.; third party payers (including governmental agencies) may not
reimburse for the use of Ampyra or our other products at acceptable
rates or at all and may impose restrictive prior authorization
requirements that limit or block prescriptions; the risk of unfavorable
results from future studies of Ampyra or from our other research and
development programs, including Plumiaz, and CVT-301, or any other
acquired or in-licensed programs; we may not be able to complete
development of, obtain regulatory approval for, or successfully market
Plumiaz, CVT-301 or any other products under development; we may need to
raise additional funds to finance our expanded operations and may not be
able to do so on acceptable terms; the occurrence of adverse safety
events with our products; delays in obtaining or failure to obtain
regulatory approval of or to successfully market Fampyra outside of the
U.S. and our dependence on our collaboration partner Biogen Idec in
connection therewith; competition; failure to protect our intellectual
property, to defend against the intellectual property claims of others
or to obtain third party intellectual property licenses needed for the
commercialization of our products; failure to comply with regulatory
requirements could result in adverse action by regulatory agencies; and
the ability to obtain additional financing to support our operations.
These and other risks are described in greater detail in Acorda
Therapeutics' filings with the Securities and Exchange Commission.
Acorda may not actually achieve the goals or plans described in its
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in this
release are made only as of the date hereof, and Acorda disclaims any
intent or obligation to update any forward-looking statements as a
result of developments occurring after the date of this release.
Source: Acorda Therapeutics